Results

Total Results: 1,134 records

Showing results for "days".

181. Prehospital EMS Blood Transfusion and Fluid Interventions for Hemorrhagic Shock (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/ems-blood-transfusion-protocol-amendment.pdf
     February 04, 2025 - We will exclude studies reporting outcomes beyond 30 days post-injury, since multiple other factors … /survival o To arrival at hospital o To hospital discharge o Any period less than or equal to 30 days … Extended, Modified Rankin Scale, Cerebral Performance Category • Length of stay o Hospital free days … o ICU free days Intermediate Outcomes in the prehospital or ED setting • Physiological indicators … solution combined with blood • Cost-effectiveness, other outcomes Timing • Outcomes up to 30 days

182. Treatments for Acute Pain: A Systematic Review (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/ehc-protocol-acute-pain-treatments.pdf
     August 08, 2019 - behaviors to avoid actual or potential tissue injuries.”3 Acute pain usually lasts for less than 7 days … but often extends up to 30 days;4 for some conditions, acute pain episodes may recur periodically. … chronic pain, but included one recommendation to limit opioids for acute pain in most cases to 3 to 7 days … Days' supply of initial opioid analgesic prescriptions and additional fills for acute pain conditions

183. Nursing-Staff-Shortages-Rapid-Research-Appendix-C (xls file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/nursing-staff-shortages-rapid-research-appendix-c.xlsx
     January 01, 2024 - department EMR Electronic medical record FEN Foreign-educated nurses HPPD Productive hours per patient days … paired nurses collaborating to perform their duties and provide care, and lasted 24 hours a day, 7 days … PSEs per 1000 patient-days was not significantly different between the 2 groups (10.3 [95% confidence … (± 15) during winter 2012 and 8 days (± 11) during summer 2012 (p < .01) Decrease in mean (SD) triage … increased by 0.33 (2014), 0.42 (2015), and 0.46 (2016) registered nurses hours per adjusted patient days

184. Cer-250-Cannabis-Table-E5-2022-Update 0 (xls file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-250-cannabis-table-e5-2022-update_0.xlsx
     January 01, 2022 - Baseline: 1,514 4-year followup: 1,217 Groups unclear A: Self-reported frequent cannabis use (≥20 days

185. Roblin_final (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/roblin.pdf
     January 01, 2010 - of diabetes participants had  connected  components and   completed one transmission within 5 days … Organize Communication: Message Delivery (2) • Decisions: o Text messages would be limited to every 5 days

186. S96 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/s96.pdf
     October 01, 2007 - We assessed system timeliness by calculating the number of days from date of ED visit to entry of case … abstraction and ADE surveil- lance, independently examined all ED medical records from randomly selected days … Up to 1200 charts or up to 20 days of charts were retrieved from each hospital. … In 2004, 67% of cases were reported to CPSC within 7 days of the ED visit, and 93% of cases were reported … within 30 days.

187. Executive summary_Comparative Effectiveness Review No. 250_Living Systematic Review on Cannabis and Other Plant-Based Treatments for Chronic Pain: 2024 Update (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-250-cannabis-2024-surv-rep-update-executive-sum.pdf
     January 01, 2024 - Executive summary_Comparative Effectiveness Review No. 250_Living Systematic Review on Cannabis and Other Plant-Based Treatments for Chronic Pain: 2024 Update Comparative Effectiveness Review Number 250 Living Systematic Review on Cannabis and Other Plant-Based Treatments for Chronic Pain: 2024 Update Exec…

188. App-F1-Surv-Report-1-Nonopioid-Pharmacol-Chronic-Pain (xls file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/app-f1-surv-report-1-nonopioid-pharmacol-chronic-pain.xlsx
     May 29, 2025 - NPP_Pain Table F-1a. Pain severity for neuropathic pain Author, Year Quality Pain Population Drug Class 1 Drug Class 2 Drug 1 Drug 2 Measure Name Measure Scale Assessment Time (Wk) Time Category Grp 1 Baseline N Grp 1 Baseline Mean Pain Score Grp1 Baseline Variance Type Grp1 Baseline Variance Grp1 Baseline Lower Limi…

189. Hypertension-Pulmonary-Arterial Research-Protocol (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/hypertension-pulmonary-arterial_research-protocol.pdf
     January 30, 2013 - managing PAH (diagnostic thinking efficacy and therapeutic efficacy) and on intermediate-term (≤90 days … ) and long-term (>90 days) patient outcomes (patient outcome efficacy)? … therapy (line infection, site pain, abrupt catheter occlusion) • Timing: o Intermediate-term (≤120 days … , 4 months, 16 weeks are the usual time points for the efficacy studies) o Long-term (>120 days, 4 … (line infection, site pain, abrupt catheter occlusion)   None Timing Intermediate-term (≤120 days

190. Disposition of Comments Report for Evidence Report 215 Safety of Vaccines Used for Routine Immunization in the United States (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/vaccine-safety_disposition-comments.pdf
     January 01, 2020 - or 42 days? … If the reason is that different studies define it as 30 and 42 days, would explain. … We assume that the short term was defined as “within 30-42 days” because some studies used 30 days, … while others used 42 days. … Table 10, Page 73 (3) Zostavax Dose 1 is indicated as being administered at 0 Days.

191. Executive summary_Comparative Effectiveness Review No. 250_Living Systematic Review on Cannabis and Other Plant-Based Treatments for Chronic Pain: 2025 Update (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-250-cannabis-2025-surv-rep-update-executive-sum.pdf
     January 01, 2025 - Executive summary_Comparative Effectiveness Review No. 250_Living Systematic Review on Cannabis and Other Plant-Based Treatments for Chronic Pain: 2025 Update Comparative Effectiveness Review Number 250 Living Systematic Review on Cannabis and Other Plant-Based Treatments for Chronic Pain: 2025 Update Exec…

192. Surveillance Report: CER 30: Comparative Effectiveness of Pain Management for Hip Fracture (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/hip-fracture-pain_surveillance.pdf
     July 08, 2015 - pharmacologic and/or nonpharmacologic pain management interventions for controlling acute (up to 30 days … Opioid dose (P > .59) on Postoperative Days 1 and 2 was not predictive of incident delirium. … Opioid dose (P > .59) on Postoperative Days 1 and 2 was not predictive of incident delirium. … There was no significant difference between groups after 30 days (OR 0.54; 95% CI 0.16, 1.77; p = … Opioid dose (P > .59) on Postoperative Days 1 and 2 was not predictive of incident delirium.

193. Cannabis-2022-Surv-Rep-3-Table-F5 (xls file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/cannabis-2022-surv-rep-3-table-F5.xlsx
     January 01, 2022 - Baseline: 1,514 4-year followup: 1,217 Groups unclear A: Self-reported frequent cannabis use (≥20 days

194. Cannabis-2022-Update-Surv-Rep-1-App-F-5 (xls file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/cannabis-2022-update-surv-rep-1-app-F-5.xlsx
     January 01, 2022 - Baseline: 1,514 4-year followup: 1,217 Groups unclear A: Self-reported frequent cannabis use (≥20 days

195. Appendix-E-Table-E5 0 (xls file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/Appendix-E-Table-E5_0.xlsx
     May 29, 2025 - Baseline: 1,514 4-year followup: 1,217 Groups unclear A: Self-reported frequent cannabis use (≥20 days

196. Cannabis-App-F5-Table-Surveillance-Report-2 0 0 (xls file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/cannabis-app-f5-table-surveillance-report-2_0_0.xlsx
     May 29, 2025 - Baseline: 1,514 4-year followup: 1,217 Groups unclear A: Self-reported frequent cannabis use (≥20 days

197. FRN 35 - Preventive Pharmacological Treatments for Migraine in Adults: Future Research Needs (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/migraine-future_research.pdf
     April 01, 2013 - per month and chronic indicating 15 or more headache days per month). … per month) and chronic (15 or more headache days per month). … Outcomes Migraine frequency, quality of life, patient satisfaction, lost work days. … Outcomes Migraine frequency, quality of life, patient satisfaction, lost work days. … Outcomes Migraine frequency, quality of life, patient satisfaction, lost work days.

198. Urinary-Incontinence-Treatment Surveillance (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/urinary-incontinence-treatment_surveillance.pdf
     October 29, 2012 - pooled analysis demonstrated that women did not experience continence for more than 7 consecutive days … The rates of more than 3 dry days/week were greater than placebo with 7.5 mg of darifenacin (RR 1.47 … (RR 1.48, 95 percent CI, 1.04 to 2.09).486 The drug had to be given to 17 women to achieve 3 dry days

199. PEPTIC ULCER #11 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pepticulcer_hi_impact.pdf
     January 01, 2012 - hospitalization and infusion of corticosteroids. 11 If the patient does not improve after 3 to 5 days … of treatment, 54% of patients treated with teduglutide were able to reduce the number of infusion days … per week by 1 or more days, compared with 23% of patients treated with placebo (p = 0.005). 28 In … Additionally, after 12 months of treatment with teduglutide, 53% of patients reduced their infusion days … per week, and 24% of patients reduced their infusion days per week by 3 or more days.

200. Leong-notes-151020 copy - Teresa (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/leong-presenation.pdf
     May 29, 2025 - Leong-notes-151020 copy - Teresa This is a very timely conversation that we’re having not only in bringing forward evidence but as leaders in academic centers, collaborators, and  AHRQ to pull together the pearls of wisdom because patients are clamoring for help. I represent that aspect of the patient population, …